Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
about
Endothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionProstacyclin for pulmonary hypertension in adultsPharmacotherapy of systemic sclerosisSelective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseHealth-related quality of life in patients with pulmonary arterial hypertensionComparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-AnalysisThe limits of oral therapy in pulmonary arterial hypertension managementPulmonary hypertension: diagnostic and therapeutic challengesDigital ulcers in systemic sclerosisHemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertensionLong term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analoguePalliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy.Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.Pulmonary hypertension: diagnosis and managementSildenafil for pulmonary hypertension.Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs [corrected]Life-threatening complications of adult-onset Still's disease.Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentTargeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysisPrognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy.Identifying "super responders" in pulmonary arterial hypertension.Therapy for pulmonary arterial hypertension associated with systemic sclerosis.Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsTransition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up.Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Predictors of venous thromboembolism in patients with advanced common solid cancersDiagnosis and management of pulmonary hypertension in systemic sclerosis.Scleroderma lung diseaseSystemic sclerosis-associated pulmonary arterial hypertensionSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseasesSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportThe establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.
P2860
Q24200714-DDBF655C-71F6-463E-BDCB-2F13977A1198Q24240009-980B63C4-E9C7-440B-AD7D-A4570CED4337Q24245506-B7B4865A-1DBB-41A4-8D66-77A93D32F28FQ24246933-6DCA0FBF-6287-4B1B-8BED-BB84C20BC49EQ24629481-61849419-3ACD-43BC-B40D-5468A8EC0DC9Q24681558-BD0FCDE9-FF65-4394-A042-0E2FCCC1703AQ24814151-C5702270-76D4-48F5-A2BB-D08753220058Q26772960-AC278713-DD9D-42E1-A767-0D57BC96073EQ26773209-43316E86-6BB8-4DA7-9B05-EA0874664F1FQ26796434-54A7AE73-1D8F-4406-B097-242DB44A3DF6Q28080196-8DF84459-C527-4C54-A0F2-CDB5AAD3827DQ28083099-4AE13AA2-9CC8-4163-AC84-A7D47B95D331Q28364280-177C1E1F-CC1A-4930-8486-D60F410ABE68Q33146617-6426623A-040B-4120-B935-A40BAF8515B8Q33156291-5C65CB67-8574-4FD4-B21D-474DF49D999AQ33157071-EEE72119-6E06-40F6-992E-70710026A22BQ33213984-70504C51-99DA-4822-B8F6-A08CD5531A61Q33405650-AEB6F23A-DCC2-47FE-B610-7932C92BBE0CQ33412732-3951EADF-91DD-49B7-9710-31468372878BQ33430747-03AF4F2D-B217-4296-B3D3-3E2F67998DFEQ33431527-FFFBBF98-C130-4870-9A67-608A2DFE364EQ33532813-B28B50E9-4393-478B-8BBA-5E85DD9EC258Q33573360-388B032E-B0BC-4734-947B-45B1AB4D64D6Q33673947-FF949B73-828B-4E1B-AF51-BDF8D356759BQ33715766-B02617C6-5DBD-4C40-B18D-EE20E3F22D3AQ33787275-804B2DE4-FE54-4639-8E74-3141E0EE2F25Q33788452-00E15CA3-4209-4E39-920C-991BBC066F61Q33805746-30A3677C-7968-48B5-B936-47A97A693615Q33806168-FED817D2-B9ED-4414-97F7-497CCAE88520Q33806206-BED82564-42D5-44F9-BCDD-37D2533A7EA3Q33810499-828EA01E-E0C3-4001-8095-78AF134CB634Q33810510-6B77DBFC-6727-4F6F-831D-FC65AB363E42Q33832379-23DFF462-95D6-46DB-8AFD-AD54C2881A2DQ33919119-8302480C-2A8B-4B60-A156-FF7486520BFCQ33950086-39738DB9-2420-4D42-B77A-FF5DF740E561Q33965825-6EEAB477-8D36-421E-B5C3-0F014FB11244Q33965898-C2CDE546-AEBD-4312-9DF5-6496B5DC8B69Q34032884-F4EA1153-BEBF-4B49-8287-7C3A1F64326FQ34064492-358208E9-7BCF-49E3-B05B-FAF335656C57Q34109161-738F87F7-FFDC-4D0A-ABBE-17ACFA71D5D7
P2860
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Continuous intravenous epopros ...... A randomized, controlled trial
@ast
Continuous intravenous epopros ...... A randomized, controlled trial
@en
Continuous intravenous epopros ...... A randomized, controlled trial
@nl
type
label
Continuous intravenous epopros ...... A randomized, controlled trial
@ast
Continuous intravenous epopros ...... A randomized, controlled trial
@en
Continuous intravenous epopros ...... A randomized, controlled trial
@nl
prefLabel
Continuous intravenous epopros ...... A randomized, controlled trial
@ast
Continuous intravenous epopros ...... A randomized, controlled trial
@en
Continuous intravenous epopros ...... A randomized, controlled trial
@nl
P2093
P3181
P1476
Continuous intravenous epopros ...... A randomized, controlled trial
@en
P2093
B H Brundage
B M Groves
C G Elliott
D B Badesch
D Langleben
F M Wigley
I M Robbins
P304
P3181
P356
10.7326/0003-4819-132-6-200003210-00002
P407
P577
2000-03-21T00:00:00Z